Nuvectis Pharma (NVCT) Common Equity (2021 - 2026)

Nuvectis Pharma (NVCT) has 6 years of Common Equity data on file, last reported at $14.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 32.14% year-over-year to $14.2 million; the trailing twelve-month figure through Mar 2026 stood at $14.2 million (down 32.14% YoY), and the FY2025 full-year result was $18.4 million, up 89.57% from the prior year.
• Common Equity fell to $14.2 million in Q1 2026, from $18.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $24.0 million in Q3 2025 to a low of $9.7 million in Q4 2024.
• A 5-year average of $15.5 million and a median of $14.2 million in 2026 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 361.36% in 2022 and sank 38.38% in 2024, its largest moves.
• Tracing NVCT's Common Equity over 5 years: stood at $14.2 million in 2022, then declined by 14.19% to $12.2 million in 2023, then fell by 20.39% to $9.7 million in 2024, then surged by 89.57% to $18.4 million in 2025, then declined by 22.77% to $14.2 million in 2026.
• Business Quant data shows NVCT's Common Equity at $14.2 million in Q1 2026, $18.4 million in Q4 2025, and $24.0 million in Q3 2025.